Sonnet BioTherapeutics Holdings, Inc.
SONN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1,000 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $22 | $22 | $22 | $22 |
| Gross Profit | -$22 | -$22 | -$886 | -$22 |
| % Margin | – | – | -88.6% | – |
| R&D Expenses | $2,426 | $1,885 | $1,886 | $1,199 |
| G&A Expenses | $1,381 | $2,345 | $1,963 | $1,974 |
| SG&A Expenses | $1,381 | $2,345 | $1,963 | $1,974 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$22 | -$22 | -$1,886 | -$22 |
| Operating Expenses | $3,784 | $4,207 | $1,963 | $3,152 |
| Operating Income | -$3,806 | -$4,229 | -$2,849 | -$3,173 |
| % Margin | – | – | -284.9% | – |
| Other Income/Exp. Net | $31 | $738 | -$153 | $45 |
| Pre-Tax Income | -$3,776 | -$3,491 | -$3,002 | -$3,129 |
| Tax Expense | $0 | $0 | $158 | $0 |
| Net Income | -$3,776 | -$3,491 | -$3,161 | -$3,129 |
| % Margin | – | – | -316.1% | – |
| EPS | -0.95 | -0.89 | -1.56 | -4.81 |
| % Growth | -6.7% | 42.9% | 67.6% | – |
| EPS Diluted | -0.95 | -0.89 | -1.56 | -4.81 |
| Weighted Avg Shares Out | 3,965 | 3,922 | 2,023 | 650 |
| Weighted Avg Shares Out Dil | 3,965 | 3,922 | 2,023 | 650 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $22 | $22 | $22 | $22 |
| EBITDA | -$3,754 | -$4,207 | -$2,827 | -$3,152 |
| % Margin | – | – | -282.7% | – |